Suchen
PepGen Inc
PEPGZur Watchlist hinzufügen
2.980USD
0.0000.00%
Trading geöffnet 09/14, 13:21（ET）
206.39MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über PepGen Inc Unternehmen
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
PepGen Inc Profil
BörsenkürzelPEPG
Name des UnternehmensPepGen Inc
IPO-datumMay 06, 2022
CEOMcArthur (James G)
Anzahl der mitarbeiter81
WertpapierartOrdinary Share
GeschäftsjahresendeMay 06
Addresse245 Main St, 2nd Floor
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142
Telefon17034568000
Websitehttps://pepgen.com
BörsenkürzelPEPG
IPO-datumMay 06, 2022
CEOMcArthur (James G)
Führungskräfte von PepGen Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James G. McArthur, Ph.D.
Dr. James G. McArthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.10K
+15.70%
Dr. James G. McArthur, Ph.D.
Dr. James G. McArthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.10K
+15.70%
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research and Development
Executive Vice President, Head of Research and Development
--
--
Dr. Mitchell H. Finer, Ph.D.
Dr. Mitchell H. Finer, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. James G. McArthur, Ph.D.
Dr. James G. McArthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.10K
+15.70%
Dr. James G. McArthur, Ph.D.
Dr. James G. McArthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.10K
+15.70%
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von PepGen Inc?
Die fünf größten Anteilseigner von PepGen Inc sind: Dr. James G. McArthur, Ph.D.
Wie viele Institutionen halten Anteile an PepGen Inc (PEPG)?
Mit Stand vom 2026Q1 halten 209 Institutionen Anteile an PepGen Inc, mit einem Gesamtmarktwert von etwa 66.38M, was 95.96% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2071901.00 gestiegen.